Melanotan-2 (MT-2) is a synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH) that activates melanocortin receptors — primarily MC1R — to stimulate melanin production. In the original Phase I clinical trial, just 5 low-dose subcutaneous injections produced measurable pigmentation increases in 2 of 3 subjects (Dorr et al., 1996).
Research-context information only. Melanotan-2 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
But "measurable" in a lab and "visible tan" in a mirror are different things. The timeline depends almost entirely on one variable: Fitzpatrick skin type.
This guide breaks down what to realistically expect at each stage — from first injection through long-term maintenance — based on published clinical data and documented user reports. This is not medical advice. MT-2 has no FDA approval for any indication.
Before looking at timelines, the starting point matters. Fitzpatrick skin type determines baseline melanocyte density, melanin production capacity, and how visibly skin responds to MT-2.
Fitzpatrick Type
Description
MT-2 Response Speed
Typical Loading Duration
I
Always burns, never tans
Slowest — 3-4+ weeks for subtle change
4-6 weeks
II
Burns easily, tans minimally
Slow — 2-3 weeks for noticeable change
3-4 weeks
III
Burns moderately, tans gradually
Moderate — 1-2 weeks for visible darkening
2-3 weeks
IV
Burns minimally, tans easily
Fast — 5-10 days for noticeable results
2 weeks
V-VI
Rarely/never burns, dark baseline
Fastest — but least "dramatic" change
1-2 weeks
Type I skin has fewer active melanocytes and produces predominantly pheomelanin (reddish-yellow pigment) rather than eumelanin (brown-black). MT-2 can shift this ratio, but the process takes significantly longer than in skin types that already produce eumelanin efficiently.
Key point: Type I-II progress is not comparable to Type III-IV reports online. The underlying biology is fundamentally different.
Weeks 2-4: Visible Tan Development
This is where most users see the results they signed up for. Melanocytes are now actively producing and depositing melanin in the epidermis, and the cumulative effect of daily dosing becomes visually obvious.
What to Expect
Weeks 2-3:
Face, neck, and arms are noticeably darker. The tan appears most concentrated on areas receiving any UV exposure.
The color quality shifts from a "dirty" or uneven initial darkening to a more natural-looking bronze tone.
Uneven tanning is common — areas with more melanocytes (face, shoulders, forearms) darken faster than torso or legs.
Freckles may become quite pronounced. Existing moles continue to darken. Mole changes warrant careful monitoring — see the Melanotan-2 side effects guide; a baseline dermatological screening is the documented precaution.
Weeks 3-4:
Most Type III-IV users have achieved a significant visible tan by this point.
Type II users are catching up — a noticeable "warm glow" that others will comment on.
Type I users may have a subtle but real change: a shift from "paper white" to "warm ivory" or light golden tone.
Appetite suppression may plateau or normalize slightly as MC4R desensitization occurs.
Sexual side effects remain consistent in most users throughout active dosing.
The UV Multiplier
MT-2 and UV exposure work synergistically. Clinical research on the related compound melanotan-1 demonstrated that melanocortin peptides combined with UV exposure produced significantly enhanced tanning compared to UV alone — and the tan lasted 3+ weeks longer (Levine et al., 2004).
Aggressive UV exposure is not required. Community sources report that even 10-15 minutes of incidental sun exposure on dosing days dramatically accelerates results. Self-reported tanning-bed sessions are kept brief (5-10 minutes) and infrequent. The goal is activation, not burning.
Without UV exposure, results are markedly reduced. MT-2 primes the melanocytes, but UV provides the trigger signal to produce and distribute melanin into the skin layers.
By 4-8 weeks of loading, most users have reached or are approaching their desired pigmentation level. This is the transition point from loading to maintenance dosing.
What to Expect
Full tan established for Type III-IV users (typically by week 4-5). Type I-II users may need the full 6-8 weeks.
Color stabilization — the tan looks more even and natural as melanin distribution equalizes across skin areas.
Maintenance transition — loading dose (daily 250-500mcg) shifts to maintenance (500mcg 1-2x per week). Some users maintain on even less frequent dosing.
Side effects at maintenance are minimal. Nausea is typically absent at this stage. Appetite effects and sexual effects persist but are milder with less frequent dosing.
Mole monitoring remains critical. A qualitative study of MT-2 users found that mole darkening and new mole formation were among the most commonly reported longer-term effects (Evans-Brown et al., 2021). A dermatological skin check is the documented precaution at this stage.
Maintenance Dosing Protocol
The goal of maintenance is to sustain melanin levels with the minimum effective dose:
Skin Type
Typical Maintenance Dose
Frequency
Type I-II
500mcg
2x per week
Type III-IV
250-500mcg
1-2x per week
Type V-VI
250mcg
1x per week or less
With consistent UV exposure (even incidental), many users find they can reduce maintenance frequency over time. Without UV, maintenance doses need to be more frequent to preserve pigmentation.
Months 3+: Long-Term Considerations
Users on long-term MT-2 maintenance report stable tanning results with minimal side effects. However, several long-term considerations deserve attention.
Sustained Effects
Tan quality improves over months as melanin distribution becomes more uniform.
Dose requirements may decrease. Many long-term users find they need less frequent maintenance dosing over time.
Seasonal adjustment — users in northern latitudes with minimal winter UV may need slightly higher maintenance frequency in winter months, or accept some fading.
Safety Monitoring
Dermatological screening every 3-6 months is the commonly documented precaution during active use. At least one case report has documented melanoma emergence during MT-2 use in combination with tanning bed exposure (Reid et al., 2013). While causation was not established, melanocyte stimulation warrants ongoing vigilance.
Mole tracking using the ABCDE criteria (asymmetry, border, color, diameter, evolving) is the documented approach; baseline photographs allow comparison.
Blood pressure monitoring — MT-2 can cause transient blood pressure elevations. See the Melanotan-2 bloodwork guide for the full monitoring panel.
What Happens After Stopping
Week 1-2 after stopping: No immediate visible change. Melanin already deposited in the skin remains.
Weeks 4-8: Most of the MT-2 enhanced tan has faded. Rate depends on skin type and ongoing UV exposure.
Full return to baseline: 2-3 months for most users, though some report residual pigmentation lasting longer, particularly in freckles.
Bac Water Made for Peptides50% off
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
Genetic melanocyte density and melanin type (eumelanin vs. pheomelanin) determine the ceiling and speed. Type I skin has a fundamentally lower ceiling than Type IV — MT-2 cannot override genetics, only optimize the existing capacity.
2. UV Exposure
The single most controllable accelerator. Even brief, regular UV exposure (10-15 minutes of sunlight) dramatically outperforms zero UV. However, the goal is activation, not sunburn. Burning while on MT-2 is still burning — the peptide provides some photoprotective benefit but does not confer immunity to UV damage.
3. Dose and Consistency
Daily dosing during loading matters more than high individual doses. A consistent 250mcg daily protocol will outperform sporadic 500mcg doses. Missing days extends the loading timeline proportionally.
4. Injection Site and Method
Subcutaneous injection is the standard route. Nasal spray formulations exist but have significantly lower bioavailability and less predictable absorption. Slow results on nasal MT-2 may trace to this.
Areas with higher melanocyte density (face, shoulders, forearms) tan first and fastest. Torso, legs, and areas typically covered by clothing lag behind. Areas that receive direct UV exposure will always outpace covered areas.
This is the primary use case and follows the timeline above. Peak tanning results typically occur at 4-6 weeks for most skin types.
Sexual Function (MC4R)
Sexual effects are among the earliest and most consistent MT-2 responses. In a double-blind placebo-controlled trial, MT-2 initiated erections in 17 of 20 men with erectile dysfunction, and 68% reported increased sexual desire versus 19% on placebo (Wessells et al., 2000).
Timeline:
First dose: Many users report increased libido and spontaneous erections within 1-5 hours of the first injection.
Loading phase: Effects are consistent with each dose. They typically begin 1-3 hours post-injection and last 4-8 hours.
Maintenance: Sexual effects persist but are less intense with lower dosing frequency. They tend to correlate directly with dose timing.
Appetite Suppression (MC4R)
MT-2's anorectic effect is mediated through the same MC4R pathway that regulates satiety. Animal studies show significant food intake reduction with intermittent MT-2 dosing, with robust fat loss that persists even after food intake normalizes (Grieco et al., 2010).
Timeline:
First dose: Appetite suppression is noticeable from day one for most users.
Weeks 1-2: Strongest appetite suppression during daily loading. Some users report difficulty eating enough.
Weeks 3-4: Partial tolerance develops. Appetite suppression is still present but less dramatic.
Maintenance: Effects diminish with less frequent dosing. This is primarily a loading-phase benefit.
Mild side effects (nausea, flushing) that decrease over days
Noticeable tan difference between UV-exposed and covered areas
Signs to Reassess
No visible change after 3 weeks of consistent loading (Type III+): common troubleshooting steps described by community sources are checking product quality, confirming UV exposure, and confirming reconstitution was done correctly.
No change after 4-5 weeks (Type I-II): community sources describe increasing the loading dose to 500mcg if tolerated. Some very fair-skinned individuals self-report needing higher cumulative doses.
New moles or changing moles: dermatological evaluation is the documented response, regardless of how the tan is progressing.
Unusual symptoms (severe headache, chest pain, vision changes): rare but serious adverse events including rhabdomyolysis have been reported (Hjuler & Bhalla, 2012).
When to Stop
There is no established maximum duration for MT-2 use. However, reasonable stopping points include:
Goal achieved: the desired tan level is reached and can be maintained with minimal dosing.
Mole concerns: Any dermatological findings that warrant discontinuation.
Side effect burden: If side effects are not acceptable even at low doses.
Seasonal: Some users cycle MT-2 only during spring/summer and allow the tan to fade in winter.
Frequently Asked Questions
How long does Melanotan-2 take to work?
Most users notice initial skin darkening within 5-10 days of loading at 250-500mcg daily. However, Fitzpatrick skin type is the biggest variable — Type III-IV skin may darken noticeably within the first week, while Type I-II skin often takes 2-3 weeks to show visible change. A full tan typically develops over 3-6 weeks of loading.
Why am I not tanning on Melanotan-2?
The three most common reasons: insufficient UV exposure (MT-2 needs at least some UV trigger), too-low dosing (under 250mcg/day during loading), or very fair skin (Fitzpatrick Type I) which simply takes longer and produces a more subtle result. Community sources describe 10-15 minutes of UV exposure on injection days as the key accelerator.
Does Melanotan-2 work without sun exposure?
MT-2 stimulates melanocyte activity, but UV light is the trigger that activates melanin production in the skin. Without any UV exposure, results will be minimal or absent. Even brief incidental sun exposure (10-15 minutes) dramatically improves results compared to zero UV.
How long do Melanotan-2 results last after stopping?
A well-established tan from MT-2 typically fades over 4-8 weeks after stopping, depending on skin type and ongoing UV exposure. The melanin already deposited in skin degrades naturally through cell turnover. Maintenance dosing (1-2 times per week) can preserve results indefinitely.
What do community sources describe about accelerating Melanotan-2 results?
Moderate UV exposure on dosing days is described as the single most effective accelerator. Beyond that, consistent daily dosing during the loading phase matters more than increasing the dose. Higher doses primarily increase side effects (nausea, flushing) without proportionally faster tanning.
Research Supplies for Melanotan II
Hand-picked storage, injection, and recovery supplies paired with Melanotan II protocols.
Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. PMID: 8637402
Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12(Suppl 4):S74-S79. PMID: 11035391
Wessells H, Fuciarelli K, Hansen J, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641-646. PMID: 11018622
Levine N, Dorr RT. Tanning and its role in skin cancer prevention: the potential of superpotent melanotropic peptides and sunlight. Arch Dermatol. 2004;140(8):998-1002. PMID: 15262693
Grieco P, Cai M, Han G, et al. Intermittent MTII application evokes repeated anorexia and robust fat and weight loss. Peptides. 2010;31(7):1208-1214. PMID: 20034526
Evans-Brown M, McVeigh J, Perkins C, Bellis MA. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Perform Enhanc Health. 2021;9(3):100203. PMID: 34464955
Reid C, Fitzgerald T, Fabre A, Kirby B. Melanoma associated with the use of melanotan-II. Dermatology. 2013;227(4):301-303. PMID: 24355990
Hjuler KF, Bhalla A. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012;50(10):1054. PMID: 23121206
